Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer sees Champix receive further international approval

Pfizer sees Champix receive further international approval

31st January 2008

Following the launch of Pfizer’s smoking cessation aid in the US and the European Union (EU), Japan has now granted marketing and manufacturing authorisation for the oral aid Champix.

Champix is already approved in more than 60 countries around the world and used for smokers who want to kick the habit.

The approval follows a 12-week study in Japanese smokers who wanted to quit smoking with the primary endpoint being a four consecutive-week smoking cessation between week nine and week 12.

Over 85 out of 130 cases achieved the primary endpoint giving a rate of 65.4 per cent for patients receiving one milligram of Champix twice-daily compared to a 39.5 per cent rate in a placebo group.

Champix is Japan’s first oral smoking cessation aid and relieves withdrawal symptoms and tobacco craving by acting as an agonist for nicotine receptors in the brain which are associated with nicotine dependence.

It also acts as an antagonist to inhibit nicotine from binding to the receptors when a person smokes when receiving treatment, so as to limit the patient’s sense of satisfaction from smoking.

Champix was approved in the EU in December 2006.

Earlier this month, Pfizer noted that there were few actions an individual can take that provide greater health benefits than the decision to quit smoking.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.